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Aims: There is mounting evidence that use of B vitamins can help control neuropathic pain. This study inves-
tigated if treatment with B1, B6 and B12 vitamins, alone or in combination with carbamazepine, can amelio-
rate distinct nociceptive behaviors in a model of trigeminal neuropathic pain.
Main methods: Male Wistar rats were submitted to infraorbital nerve constriction or sham surgery and re-
ceived a 5-day treatment with one of the B vitamins, a single carbamazepine injection or the association of
both treatments and were tested for facial thermal and mechanical hyperalgesia at different time intervals.
Key ﬁndings: Repeated treatment with B1 (thiamine), B6 (pyridoxine) and B12 (cyanocobalamin) vitamins
(at 180, 180 and 18 mg/kg/day, respectively, for 5 days) prevented the development of heat hyperalgesia
after infraorbital nerve injury, but only B12 and B6 treatments attenuated cold and mechanical hyperalgesia,
respectively. A single injection of carbamazepine (30 mg/kg) signiﬁcantly reduced thermal, but not mechanical,
hyperalgesia after nerve injury. Combinations of lower doses of each B vitamin (B1 and B6 at 18 mg/kg/day and
B12 at 1.8 mg/kg/day for 5 days) with carbamazepine (10 mg/kg) markedly reduced heat hyperalgesia after
infraorbital nerve injury. Treatment with B12 (1.8 mg/kg/day) combined with carbamazepine (10 mg/kg) also
synergized to attenuate cold hyperalgesia at some time points, but combination of B6 (18 mg/kg/day) with
carbamazepine (30 mg/kg) failed to modify mechanical hyperalgesia.
Signiﬁcance:We suggest that B vitamins might constitute a relevant adjuvant to control some aspects of the pain
afﬂicting patients suffering from trigeminal neuropathic pain.© 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Chronic neuropathic pain caused by lesions in the peripheral or
central nervous system comes in various forms which are still difﬁcult
to control and treat. Trigeminal neuralgia, continues to represent a
therapeutic challenge as its pathophysiology is not yet fully under-
stood (Adams, 1989; Alves et al., 2004; Chichorro et al., 2006a,
2006b; Cuellar et al., 2010; Eide and Rabben, 1998; Fisher et al.,
2003; Kleef et al., 2009; Sindrup and Jensen, 2002; Zakrzewska,
2004). Currently, anticonvulsant drugs are commonly used to control
symptoms in neuropathic pain, especially for their ability to reduce
neuronal excitability by acting through different mechanisms (Attal
et al., 2010; Delzell and Grelle, 1999; Finnerup et al., 2010a, 2010b;
Gill et al., 2011; Martin and Forouzanfar, 2011; Willimann, 2011;
Zakrzewska and McMillan, 2011). The most studied agents are carba-
mazepine, gabapentin and pregabalin, but lamotrigine, topiramate
and oxcarbazepine have also shown analgesic potential in different
pain models and in clinical studies (Ambrósio et al., 2002; Chengna, Biological Sciences Sector,
+55 41 3361 1720; fax: +55
orro).
sevier OA license.and Chiou, 2006; Cheshire, 2002; Czapinski et al., 2005; Lynch and
Watson, 2006; Siniscalchi et al., 2011; Wilhelmus and Forouzanfar,
2011). Indeed, carbamazepine is currently the ﬁrst choice for treat-
ment of trigeminal neuralgia, as it has been shown to reduce pain
symptoms in about 70% of the cases, and it is also used to diagnose
the condition (Ambrósio et al., 2002; Kleef et al., 2009). However,
continuous treatment with carbamazepine or other anticonvulsant
drugs results in numerous adverse effects such as drowsiness, dizzi-
ness, ataxia, diplopia, blurred vision, nausea, dry mouth, constipation
and diarrhea (Alves et al., 2004; Attal et al., 2010; Zakrzewska and
Patsalos, 1992). In addition, many patients submitted to repeated car-
bamazepine treatment become refractory to the medication (Attal et
al., 2010; Boto, 2010; Bergouignan, 1970; Zakrzewska and Patsalos,
1992). Thus, additional therapeutic options are in high demand
(Boto, 2010; Zakrzewska et al., 2005a, 2005b).
Thiamine, pyridoxine and cyanocobalamin (i.e. B1, B6 and B12
vitamins) are the major vitamins of B complex. They act mainly as
coenzymes of different reactions, participating importantly in the
metabolism of carbohydrates, proteins and lipids. They also play an
important role in the formation of new cells, DNA, RNA and myelin
(Dakshinamurti et al., 2003; Depeint et al., 2006a, 2006b; Healton
et al., 1991; McCombe andMcLeod, 1984; Selhub et al., 2010). According
to some studies, B vitamins present neuroprotective effects, which
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of neuropathic pain (Jolivalt et al., 2009; Mixcoatl-Zecuatl et al., 2008;
Reyes-Garcia et al., 2004; Wang et al., 2005; Zimmerman et al., 1990).
However, to the best of our knowledge, the inﬂuence of the vitamins
of B complex on orofacial pain has never been investigated. Thus, the
present study aimed to evaluate the inﬂuence of the administration
of B1, B6 and B12 vitamins of the B complex, either delivered alone
or combined with carbamazepine treatment, in thermal and mechan-
ical hyperalgesia in a model of trigeminal neuropathic pain induced
in rats by constriction of the infraorbital nerve.Materials and methods
Animals
Experiments were conducted on male Wistar rats weighing
180–220 g, maintained ﬁve to a cage at controlled temperature
(22±1 °C) under a 12/12 h light/dark cycle (lights on at 08:00 h)
with free access to chow and tap water. They were acclimatized to the
laboratory for at least 48 h before use. The experimental procedures
were previously approved by UFPR's institutional Committee on the
Ethical Use of Animals (authorization # 471), where the study was
carried out, and conducted in accordance with the ethical guidelines
of the International Association for the Study of Pain (Zimmermann,
1983) and Brazilian regulations on animal welfare. All efforts were
made to minimize the number of animals used and their suffering.Constriction of the infraorbital nerve
The constriction of the infraorbital nerve (CION) was performed
according to the slight modiﬁcation of the procedure originally pro-
posed by Vos et al. (1994) described by Chichorro et al. (2006a).
Brieﬂy, rats were anesthetized with an intraperitoneal (i.p.) injection
of amixture of ketamine and xylazine (50 and 10 mg/kg, respectively)
and an incision was made in the skin of the snout, under the right eye,
about 3 mm caudal to the mystacial pads. The superior lip elevator
and anterior superﬁcial masseter muscles were bluntly dissected to
expose the rostral end of the infraorbital nerve, as it emerged from
the infraorbital ﬁssure. Special care was taken to not damage the facial
nerve. Two silk 4‐0 ligatures were then tied loosely and 2 mm apart
around the infraorbital nerve and the wound was closed with addi-
tional silk sutures (4‐0). Sham-operated rats were treated identically,
but no ligatures were applied to the infraorbital nerve. After surgery,
all rats were maintained in a warm room until they recovered from
anesthesia.Cold stimulation
Before each testing session, animals were placed in individual
plastic observation cages and left to adapt to the environment for at
least 30 min. After this period, they usually displayed considerable
snifﬁng, but very little locomotor activity. Cold stimulation was
applied by the experimenter in the form of a brief 1-s spray of
tetraﬂuoroethane to the center of the right vibrissal pads, while
gently restraining the animal in its cage by placing one hand around
its trunk. The total duration of bilateral facial grooming behavior
with both forepaws directed to the snout was recorded, using a stop-
watch, over the ﬁrst 2 min following application of the cold stimulus,
as an index of the intensity of nocifensive responsiveness. In rats
subjected to CION, cold responsiveness was evaluated before and on
days 2, 4, 6, 9 and 12 after surgery. It is important to point out that
cold hyperalgesia peaks on days 4 to 6 after CION surgery, as previ-
ously reported by our group (Chichorro et al., 2006a).Heat stimulation
Thermal hyperalgesia on the orofacial area was measured as pre-
viously described (Chichorro et al., 2009). On each occasion, the
animal was temporarily removed from its home cage and gently
held by the experimenter and a radiant heat source was positioned
1 cm from the surface of the right vibrissal pad. The latency to display
either head withdrawal or vigorous ﬂicking of the snout was recorded
(in s) using a stopwatch, and a 20 s cut-off time was used to prevent
tissue damage. Reaction to heat stimulation was evaluated before
(basal responsiveness) and on days 2, 4, 6, 9 and 12 after CION surgery.
It is important to point out that heat hyperalgesia peaks on days 4 to
6 after CION surgery, as previously reported by our group (Chichorro
et al., 2009).
Mechanical stimulation
To assess orofacial mechanical hyperalgesia, before each testing
session the animals were placed in individual plastic cages and left
to adapt to the environment for at least 2 h. The mechanical threshold
was measured using a graded series of 8 von Frey monoﬁlaments
ranging from 0.04 to 8 g (Semmes–Weinsteinmonoﬁlaments, Stoelting,
Wood Dale, IL) as described previously (Christensen et al., 1999;
Chichorro et al., 2006b). Eachmonoﬁlamentwas applied near the center
of the right vibrissal pad, to the point of bending, three times on the
nerve-injured side. Each stimulation series began with the ﬁlament
producing the lowest force, and proceeded up to the ﬁlament that
evoked one of the following nocifensive behaviors twice: brisk head
withdrawal, escape or attack reactions, or short-lasting facial grooming.
Only rats that did not react to application of the 8-g ﬁlament in the
preoperative tests were included in this study, to avoid unspeciﬁc
responses. It is important to point out that mechanical hyperalgesia
starts to develop around 10 days after CION surgery, as previously
reported by our group (Chichorro et al., 2006b).
Drugs
B1, B6 and B12 vitamins (thiamine, pyridoxine and cyanocobala-
min, respectively) were obtained fromGalena Química e Farmacêutica
(Campinas, SP, Brazil) and were all dissolved in sterile saline solu-
tion. Ketamine was obtained from Rhobifarma Ind. Farmacêutica
(Hortolândia, SP, Brazil) and xylazine from Laboratórios König S.A.
(Avellaneda, Argentina). Carbamazepine was purchased from Sigma
(St. Louis, MO, USA) and was dissolved in saline solution containing
10% DMSO, 1% ethanol and 1% Tween 80.
Experimental protocols
To evaluate the inﬂuence of B vitamins on the thermal (heat
and cold) hyperalgesia induced by infraorbital nerve constriction,
thiamine, pyridoxine and cyanocobalamin were administrated indi-
vidually at 180, 180 and 18 mg/kg (s.c., 1 mL/kg), respectively, soon
after CION surgery (day 0) and then again daily throughout the next
4 consecutive days (day 1 through day 4 post-surgery). Control
animals were treated identically with saline (1 mL/kg, s.c.). Respon-
siveness to cold and heat stimulation was assessed before and on
days 2, 4, 6, 9 and 12 after CION surgery. When behavioral testing
coincided with days of injection (i.e. days 2 and 4 after CION surgery)
responsiveness was assessed both prior to and then again at 1 h after
the injection of the day, but on the other days responsiveness was
assessed only once. To evaluate the inﬂuence of B vitamins on the
mechanical hyperalgesia, rats received thiamine, pyridoxine and cya-
nocobalamin individually, at the same doses selected for the thermal
hyperalgesia experiments, but the treatments started on day 8 after
CION surgery and were repeated daily until day 12. The mechanical
threshold of rats was assessed before the surgery and on days 8, 10,
Fig. 1. Inﬂuence of repeated treatment with B vitamins on heat hyperalgesia induced by
CION surgery. Rats were treated daily with vitamin B1 (A), B6 (B) or B12 (C), at 180, 180
or 18 mg/kg/day, respectively, for 5 days, starting on the day of CION surgery. Heat
hyperalgesiawas assessed before (day 0) and ondays 2 and 4, one hour after the treatments,
and on days 6, 9 and 12 after surgery. Values representmeans±SEmean of 5–8 rats. * and #
indicate Pb0.05 when compared to corresponding value of sham- and CION-operated rats
treated with vehicle, respectively (Two way ANOVA followed by Duncan test).
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during the treatment period (i.e. days 8, 10 and 12) responsiveness was
ﬁrst assessed prior to injection and then again at 1 h after treatment of
the day. The doses of B1 and B6 vitamins were chosen based on the
study of Jolivalt et al. (2009). The dose of B12 employed was 10 times
lower than that of the other vitamins, in agreement with experimental
and clinical studies, which used B12 at different, but always lower dose
ratios compared to B1 and B6 (Allen, 2010; Caram-Salas, et al., 2004;
Depeint et al., 2006a, 2006b; Jolivalt et al., 2009; Mauro et al., 2000;
Mibielli et al., 2009). Additional groups of rats were treated with single
injections of either B1, B6 or B12 (180, 180 and 18 mg/kg, respectively,
s.c.), or vehicle (1 mL/kg, s.c.), carbamazepine (10 or 30 mg/kg, i.p.)
or the corresponding vehicle (1 mL/kg, i.p.) only on day 4 after CION
surgery and thermal hyperalgesia (to heat and/or cold stimuli) was
assessed prior to injection and also at 1-h intervals up to the fourth
hour thereafter. To evaluate effects of carbamazepine on mechanical
hyperalgesia, on day 20 after CION surgery the rats received carbamaz-
epine (30 mg/kg, i.p.) or vehicle (1 mL/kg, i.p.) and responsiveness to
mechanical stimulation of the face was assessed prior to treatment
and then again at 1-h intervals up to 4 h later. To investigate the effects
of association of different B vitamins with carbamazepine on thermal
(heat and/or cold) hyperalgesia, B1, B6 and B12 vitamins were admin-
istered individually at lower doses (18, 18 and 1.8 mg/kg/day, respec-
tively, s.c.), starting soon after CION surgery (day 0) and repeated on
the following 4 days (days 1 through 4). On day 4, immediately after
the last vitamin administration, the rats also received a single i.p.
administration of carbamazepine (10 mg/kg) and heat and/or cold
hyperalgesia was assessed at 1 h-intervals up to the sixth hour. In
addition, to investigate the effect of association of B6 with carbamaze-
pine on mechanical hyperalgesia, the vitamin was administered indi-
vidually at 18 mg/kg/day, starting on day 8 after CION surgery and
repeated on the following 4 days (days 8 through 12). On day 12, im-
mediately after the last vitamin administration, the rats also received
a single i.p. administration of carbamazepine (30 mg/kg) and mechan-
ical hyperalgesia was assessed at 1-h intervals up to the sixth hour. It is
noteworthy that different groups of rats were tested for cold, heat or
mechanical hyperalgesia experiments.
Statistical analysis and presentation of data
All data are presented as mean±S.E.M. (standard error mean) and
in instances where error bars of certain values do not appear in the
ﬁgures, it is because they were smaller than the symbol depicting
the corresponding mean value. Two-way repeated measures ANOVA
was used to analyze the data from both thermal and mechanical
stimulation, with drug treatment as the independent factor and the
different evaluation time points of nociceptive behavior as the repeat-
ed measure. In case of signiﬁcant differences with the independent
factor or with the interaction between the independent and repeated
factors, one-way ANOVA followed by the Duncan's post-hoc test, was
performed. In all statistical analysis, P values less than 0.05 were con-
sidered signiﬁcant.
Results
As previously reported by our group, CION surgery leads to the
development of orofacial sensory alterations in rats which include
hyperalgesia to cold and heat stimuli, with similar time courses
(Chichorro et al., 2006a, 2009), and a more delayed facial mechanical
hyperalgesia that only starts 10 days after the surgery (Chichorro
et al., 2006b). The present study assessed the effects of repeated
treatment with B1, B6 or B12 vitamins, alone or combined with a
single injection of carbamazepine, on changes in behavioral responses
to thermal and mechanical stimulation caused by CION injury. As
illustrated on Fig. 1, daily treatment with B1 or B6 vitamins (both at
180 mg/kg/day, s.c.) from day 0 to day 4 abolished the developmentof heat hyperalgesia in CION-injured rats compared with the control
vehicle-treated CION group (Fig. 1A and B). Moreover, vitamin B12
(at 18 mg/kg/day, s.c.) treatment also reduced orofacial heat hyper-
algesia, having displayed marked antihyperalgesic effects on days
4 and 6 (but not day 2) after surgery, and a full reversal of the
hyperalgesia on day 9 (Fig. 1C). On the other hand, when single injec-
tions of these vitamins were given on day 4 after CION surgery, those
same doses of B1, B6 and B12 each failed to inﬂuence ongoing heat
hyperalgesia for up to 4 h after administration (Fig. 2). Although
rats submitted to CION surgery also manifested orofacial cold hyper-
algesia with a time course similar to than seen for heat hyperalgesia,
daily treatment with B1 or B6 vitamins, at the same doses and over
the same period mentioned above, failed to modify the development
or to attenuate orofacial cold hyperalgesia (Fig. 3A and B). However,
treatment with B12 (18 mg/kg/day, for 5 days) reduced cold hyperal-
gesia on days 6 and 9 compared to vehicle-treated CION rats (Fig. 3C).
Interestingly, orofacial mechanical hyperalgesia after CION was sig-
niﬁcantly reduced throughout days 10 to 20 by treatment with vita-
min B6 (Fig. 4B), whereas B1 and B12 were ineffective in altering
Fig. 2. Inﬂuence of a single injection of vitamin B1, B6 or B12 on established CION-
induced heat hyperalgesia. Basal heat responsiveness was assessed before CION sur-
gery (Pre) and then again on day 4 after surgery, ﬁrst prior to (0 h) and then at each
hour after s.c. injection of vitamin B1 (A), B6 (B) or B12 (C), at 180, 180 or 18 mg/kg,
respectively. Values represent means±SE mean of 7 rats. * indicate Pb0.05 when com-
pared to corresponding value of sham-operated rats treated with vehicle (Two way
ANOVA followed by Duncan test).
Fig. 3. Inﬂuence of repeated treatment with B vitamins on cold hyperalgesia induced by
CION surgery. Rats were treated daily with vitamin B1 (A), B6 (B) or B12 (C), at 180, 180
or 18 mg/kg/day, respectively, for 5 days, starting on the day of CION surgery. Heat
hyperalgesiawas assessed before (day 0) and ondays 2 and 4, one hour after the treatments,
and on days 6, 9 and 12 after surgery. Values representmeans±SEmean of 5–7 rats. * and #
indicate Pb0.05 when compared to corresponding value of sham- and CION-operated rats
treated with vehicle, respectively (Two way ANOVA followed by Duncan test).
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and C).
Considering that carbamazepine is the ﬁrst choice treatment for
trigeminal neuralgia, we also investigated its effects on sensory alter-
ations induced by CION. Single carbamazepine (30 mg/kg, i.p.) injec-
tion on day 4 after surgery reduced heat hyperalgesia signiﬁcantly
from 2 to 4 h after administration, but at 10 mg/kg the anticonvulsant
was ineffective (Fig. 5A). Considering that CION-induced heat hyper-
algesia was amenable to the inhibition by each of the B vitamins tested
and to carbamazepine, we next assessed the inﬂuence of combinations
of lower doses of B1 (18 mg/kg/day), B6 (18 mg/kg/day) or B12
(1.8 mg/kg/day) for 5 days, together with a low dose of carbamazepine
(10 mg/kg) on day 4 after CION, in order to detect a possible synergistic
effect. Repeated daily treatmentwith vitamin B1 or B6 alone resulted in
discrete reductions of heat hyperalgesia on day 4which lasted up to 2 h
(Fig. 5B and C), but heat hyperalgesia at that time point was not
inﬂuenced by a similar treatment with B12 (Fig. 5D). In sharp contrast,
when treatmentswith B1, B6 or B12were combined on day 4 after CIONwith a dose of carbamazepine that was ineffective per se, each of the
combinations promoted a more robust and persistent reduction (up to
5 h) in heat hyperalgesia compared with each drug treatment alone,
reﬂecting a synergistic effect (Fig. 5B,C and D).
Cold hyperalgesia on day 4 after CION injury was unchanged by a
single injection of carbamazepine at 10 mg/kg, but a pronounced
antihyperalgesic effect was detected at the ﬁrst and second hours
following its administration at 30 mg/kg (Fig. 6A). Repeated 5-day
treatment with the lower dose of vitamin B12 (1.8 mg/kg) attenuat-
ed the cold hyperalgesia at 1 and 2 h after the last injection, whereas
the combination of vitamin B12 treatment with an injection of
carbamazepine (10 mg/kg) on day 4 after CION abolished cold
hyperalgesia at 1 h and also promoted signiﬁcant reductions at 2
and 4 h (Fig. 6B). At variance with the results obtained in relation
to thermal hyperalgesia, mechanical hyperalgesia on day 20 after
CION was fully resistant to alleviation either by a single injection
of carbamazepine (30 mg/kg; Fig. 7A), or by administration of the
anticonvulsant (also at 30 mg/kg) in combination with repeated
Fig. 4. Inﬂuence of repeated treatment with B vitamins on mechanical hyperalgesia in-
duced by CION surgery. Rats were treated daily with vitamin B1 (A), B6 (B) or B12 (C),
at 180, 180 or 18 mg/kg/day, respectively, for 5 days, starting on day 8 after CION
surgery. Mechanical hyperalgesia was assessed before (day 0) and on days 8, 10, 12,
16 and 20 after CION surgery. Values represent means±SE mean of 5–8 rats. * and #
indicate Pb0.05 when compared to corresponding value of sham- and CION-operated
rats treated with vehicle, respectively (Two way ANOVA followed by Duncan test).
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on day 12 after surgery (Fig. 7B).
Discussion
Vitamins of the B complex have shown efﬁcacy in controlling in-
ﬂammatory or neuropathic pain in various animal models (Bartoszyk
and Wild, 1989; Caram-Salas et al., 2006; França et al., 2001; Jolivalt
et al., 2009; Mixcoatl-Zecuatl et al., 2008) and in patients (Abbas and
Swai, 1997; Medina-Santillan et al., 2004; Simeonov et al., 1997). The
current study shows, for theﬁrst time, that repeated systemic treatment
for 5 days with vitamins B1, B6 or B12 can alleviate some of the
nociceptive changes inﬂicted by CION surgery, an animal model of tri-
geminal neuropathic pain. Whereas all three vitamins were effective
in reducing CION-induced heat hyperalgesia, cold and mechanical
hyperalgesia were amenable to suppression only by vitamins B12 andB6, respectively. In addition, both types of thermal hyperalgesia were
also susceptible to inhibition by a single injection of carbamazepine,
but mechanical hyperalgesia was not. Importantly, at doses insufﬁcient
to cause effects on its own, carbamazepine synergizedwith low doses of
each of the 3 vitamins to reduce heat hyperalgesia, and with vitamin
B12 to limit cold hyperalgesia, but no synergism towards suppression
of mechanical hyperalgesia was detected when combined with vitamin
B6.
Previous studies on the effects of B vitamins on neuropathic pain
employed different experimental models and evaluated changes in
responses evoked by nociceptive stimuli of distinct sensory modali-
ties. To facilitate comparisons between previously reported ﬁndings
in other models of neuropathy and those we obtained in the model
of CION-induced neuropathic pain, the results concerning the effects
of vitamin B treatment on heat hyperalgesia will be discussed before
those related to cold hyperalgesia and mechanical hyperalgesia.
Hind paw heat hyperalgesia induced by spinal ganglia compres-
sion or by loose ligation of the sciatic nerve in rats is reduced by single
i.p. injection of vitamins B1, B6 and B12, alone or in combination
(Song et al., 2009; Wang et al., 2005). The antihyperalgesic effect
of the combination was signiﬁcantly greater than that seen for indi-
vidual vitamins, and repeated treatment with the combination (Wang
et al., 2005) or B1 alone (Song et al., 2009) promoted long-term sup-
pression of heat hyperalgesia. In the current study, repeated adminis-
tration of each of the three vitamins was found to alleviate orofacial
heat hyperalgesia promoted by CION surgery. Vitamins B1 and B6
each provided full suppression at the highest doses tested and partial
reduction at 10-fold lower doses, whereas vitamin B12 only caused
partial reduction at the highest dose tested. It remains to be tested if
combined treatment with all 3 vitamins would result in better control
of heat hyperalgesia in thismodel of trigeminal pain. However, as single
injections of vitamins B1, B6 and B12 each failed to acutely modify heat
hyperalgesia, relief of hyperalgesia appears to require their repeated
administration.
Effects of B vitamin treatment on cold hyperalgesia associated
with models of neuropathic pain had not yet been examined. The
current study shows that repeated injections of vitamin B12 were
effective in reducing the orofacial cold hyperalgesia induced by
CION surgery. However, neither vitamin B1 nor B6 treatments modi-
ﬁed the intensity of behavioral responses to application of cold stim-
uli to the snout.
Mechanical hyperalgesia of the hind paw induced by spinal ganglia
compression or loose sciatic nerve ligation in rats were reported to be
resistant to acute administration of vitamins B1, B6 and B12, at doses
which suppressed heat hyperalgesia (Wang et al., 2005). Conversely,
in rats submitted to L5/L6 spinal nerve ligation,mechanical hyperalgesia
has been shown to be alleviated by acute administration of vitamin B12
in dose-dependent fashion (Granados-Soto et al., 2004), or by single or
combined treatment with vitamins B1, B6 and B12 (Caram-Salas et al.,
2006; Reyes-Garcia et al., 2003, 2004). In this same model, oral admin-
istration of the vitamin B1 derivative benfotiamine or vitamin B12
each reduced mechanical hyperalgesia (Mixcoatl-Zecuatl et al., 2008).
Streptozotocin-induced diabetic rats already presenting established
hind paw mechanical hyperalgesia displayed dose-related reductions
in this response following combined treatment with vitamins B1, B6
and B12 at 3 different dosage levels (Jolivalt et al., 2009). The present
study revealed that orofacial mechanical hyperalgesia induced by CION
was reduced by repeated injections of vitamin B6 alone for 5 days, but
vitamins B1 or B12 were ineffective in this regard, even though the B1
vitamin dose was identical to the higher dose tested by Jolivalt et al.
(2009).
The differences in vitamin B dosage and treatment regimens
(acute/repeated, alone/combined) used in the abovementioned studies
render it difﬁcult to draw ﬁrm conclusions as to their antihyperalgesic
activity, especially as they were obtained in various models of neurop-
athy. Overall, the limited evidence available regarding inhibition of
Fig. 5. Effect of carbamazepine alone or in combination with B vitamins on heat hyperalgesia induced by CION surgery. Basal heat responsiveness was assessed before CION surgery
(Pre) and then again on day 4 after surgery, ﬁrst prior to (0 h) and then at each hour after the injections of that day (see below). On day 4 after CION, rats received a single injection
of carbamazepine (10 and 30 mg/kg, i.p.) or vehicle (1 mL/kg, i.p.; panel A). In the subsequent panels, rats were treated daily with vehicle (saline, 1 mL/kg, s.c.) or vitamin B1 (B),
B6 (C) or B12 (D), at 18, 18 or 1.8 mg/kg/day, respectively, for 5 days, starting on the day of CION surgery and on day 4 the last injection was given simultaneously with injection of
either vehicle (1 mL/kg, i.p.) or carbamazepine (10 mg/kg, i.p.). Values represent means±SE mean of 5–9 rats. * and # indicate Pb0.05 when compared to corresponding value of
sham- and CION-operated rats treated with vehicle, respectively (Two way ANOVA followed by Duncan test).
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onstrating beneﬁcial effects of all three B vitamins. However, there
seem to be appreciable differences in the susceptibility of the mechan-
ical hyperalgesia associated to different models to suppression by vita-
mins B1, B6 and/or B12. On the other hand, considering that these
vitamins differentially affect hyperalgesia to heat, cold and mechanical
stimuli in the CION-induced model, the mechanisms through which
they suppress neuropathy-induced nociceptive sensory changes appear
to be diverse.
Carbamazepine, the primary drug of choice for treatment of tri-
geminal neuralgia, reduced established CION-induced thermal hyper-
algesia at 30 mg/kg, but mechanical hyperalgesia was unaffected. On
the other hand, mechanical hyperalgesia induced by partial sciatic
nerve ligation in rats or mice is reduced by this dose of the drug
(Walker et al., 2003), while 100 mg/kg suppressed that caused by spi-
nal nerve ligation in rats (Mixcoatl-Zecuatl et al., 2008), but this
higher dose was found to promote sedation and ataxia in our rats
(unpublished observations). Importantly, marked synergism towards
inhibition of heat hyperalgesia was observed on day 4 after CION sur-
gery when only 10 mg/kg of carbamazepine was combined with
10-fold lower doses of vitamins B1, B6 or B12, and to a lesser extent
with vitamin B12 to alleviate cold hyperalgesia, but the anticonvul-
sant drug did not synergize with low dosage vitamin B6 treatment
to modify orofacial mechanical hyperalgesia. The latter ﬁnding is
at variance with the marked synergism towards inhibition of hind
paw mechanical hyperalgesia induced by L5/L6 spinal nerve ligation
when rats were treated with a combination of gabapentin plus amixture of B1, B6 and B12 (Reyes-Garcia et al., 2004), or with carba-
mazepine or gabapentin together with either benfotiamine or vitamin
B12 (Mixcoatl-Zecuatl et al., 2008).
Various studies have sought to elucidate the mechanisms underly-
ing the inhibition of neuropathic pain by B vitamins. Alleviation of
mechanical hyperalgesia in streptozotocin-induced diabetic rats by
a mixture of vitamins B1, B6 and B12, or by vitamin B6 alone was
associated with improved sensory nerve conduction velocity (Jolivalt
et al., 2009), but no such change was found in rats rendered diabetic
with 2,5-hexanedione and treated with vitamin B6 or B12 alone
(Misumi et al., 1985). Other possible antihyperalgesic mechanisms of
B vitamins include inhibition of the diacylglycerol‐protein kinase C
(PKC) pathway (Hammes et al., 2003; Sánchez-Ramírez et al., 2006),
enhanced cGMP production by guanylylcyclase enzyme (Vesely,
1985) and increased afferent inhibitory control of nociceptive neurons
at the spinal cord (Fu et al., 1998). More recently, Song et al. (2009)
showed that B1 vitamin treatment reduced neuronal hyperexcitability
and lessen alterations of Na+ currents in injured dorsal root ganglia,
and proposed that such mechanisms might contribute to its ther-
mal antihyperalgesic effect. Considering that blockade of voltage-
dependent Na+ channels in hyperexcitable neurons of the dorsal
root or trigeminal ganglia has also been implicated in the analgesic
effect of anticonvulsant drugs in neuropathic pain (Cardenas et al.,
2006; Caviedes and Herranz, 2002; Priest, 2009), the antihyperalgesic
synergism between carbamazepine and B vitamins may be the result
of their combined action on this common target. However, the differ-
ential effects of the vitamins depending on the type of stimulus used
Fig. 6. Effect of carbamazepine alone or in combination with vitamin B12 on cold
hyperalgesia induced by CION surgery. Basal cold responsiveness was assessed before
CION surgery (Pre) and then again on day 4 after surgery, ﬁrst prior to (0 h) and
then at each hour after the injections of that day (see below). On day 4 after CION,
rats received a single injection of carbamazepine (10 and 30 mg/kg, i.p.) or vehicle
(1 mL/kg, i.p.; panel A). Alternatively, rats were treated daily with vehicle (saline,
1 mL/kg, s.c.) or vitamin B12 at 1.8 mg/kg/day, for 5 days, starting on the day of
CION surgery and on day 4 the last injection was given simultaneously with a injection
of either vehicle (1 mL/kg, i.p.) or carbamazepine (10 mg/kg, i.p.; panel B). Values
represent means±SEmean of 5–8 rats. * and # indicate Pb0.05 when compared to cor-
responding value of sham- and CION-operated rats treated with vehicle, respectively
(Two way ANOVA followed by Duncan test).
Fig. 7. Effect of carbamazepine alone or in combination with vitamin B6 on mechanical
hyperalgesia induced by CION surgery. Basal mechanical responsiveness was assessed
before CION surgery (Pre) and then again after surgery, ﬁrst prior to (0 h) and then at
each hour after the injections of that day. On day 20 after CION, rats received a single
injection of carbamazepine (30 mg/kg, i.p.) or vehicle (1 mL/kg, i.p.; panel A). In
panel B, rats were treated daily with vehicle (saline, 1 mL/kg, s.c.) or vitamin B6 at
18 mg/kg/day, for 5 days, starting on the day 8 after CION surgery and the last injection
was given simultaneously with an injection of either vehicle (1 mL/kg, i.p.) or carba-
mazepine (30 mg/kg, i.p.) on day 12 after CION. Values represent means±SE mean of
5–7 rats. * Indicate Pb0.05 when compared to corresponding value of sham-operated
rats treated with vehicle (Two way ANOVA followed by Duncan test).
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even more intriguing and further studies are still necessary to eluci-
date this issue.
Even if their analgesic mechanisms remain to be elucidated, we
regard the pre-clinical and clinical studies with B vitamins as very
promising for two main reasons: the low risk of adverse effects relat-
ed to B vitamins use, and their potential for use as adjuvants in the
control of pain. Several experimental studies reported that acute or
repeated treatment with high doses of B vitamins did not cause
signs of motor disturbance, a common side effect related to anticon-
vulsants (Medina-Santillan et al., 2004; Mixcoatl-Zecuatl et al.,
2008; Reyes-Garcia et al., 2002, 2003, 2004). In fact, neuropathic
pain patients treated with gabapentin plus B vitamins showed a de-
layed appearance of gabapentin-related side effects when compared
to those treated with anticonvulsant alone (Medina-Santillan et al.,
2004). The present study, alongside others (Caram-Salas et al., 2004,
2006; Granados-Soto et al., 2004; Mixcoatl-Zecuatl et al., 2008;
Reyes-Garcia et al., 2002, 2003, 2004), demonstrate that associationof B vitamins with drugs of other pharmacological classes, including
anticonvulsants, steroidal and non-steroidal anti-inﬂammatory drugs
enables synergism between their analgesic effects, which allows for
lowering of doses and fewer side effects.Conclusion
In conclusion, repeated treatment with vitamins B1, B6 or B12
reduces heat hyperalgesia, cold hyperalgesia (vitamin B12) and
mechanical hyperalgesia (vitamin B6) inﬂicted by CION surgery in
rats, a model of trigeminal neuralgia. At lower doses, these vitamins
synergize with carbamazepine to provide greater relief of heat and
cold hyperalgesia, but not mechanical hyperalgesia. If these ﬁndings
are reproducible in humans, B vitamins alone or in combination
with anticonvulsant drugs could represent a potentially inexpensive
and safe long-term approach in the pharmacotherapy of trigeminal
neuropathic pain in the clinic.
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